Zynerba Pharmaceuticals, Inc.
(NASDAQ CM: ZYNE)
Rigrodsky Law, P.A. is investigating Zynerba Pharmaceuticals, Inc. (“Zynerba”) regarding possible breaches of fiduciary duties and other violations of law related to Zynerba’s agreement to be acquired by Harmony Biosciences Holdings, Inc. Under the terms of the agreement, Zynerba shareholders will receive $1.1059 per share in cash.